Keywords: |
cancer chemotherapy; controlled study; unclassified drug; human cell; gene deletion; genetics; drug potentiation; multimodality cancer therapy; nonhuman; antineoplastic agents; combined modality therapy; antineoplastic agent; proteins; cell cycle protein; animal cell; mouse; animal; metabolism; animals; cell cycle proteins; mice; cell death; gene; dna repair; animal experiment; animal model; protein; small interfering rna; rna, small interfering; gene product; antineoplastic activity; cytotoxicity; in vitro study; drug effect; pathology; cell line, tumor; physiology; virology; animalia; drug synergism; drug mechanism; messenger rna; rna, messenger; tumor cell line; oncolytic virus; herpesviridae; simplexvirus; stomach cancer; gene control; herpesvirus 1, human; upregulation; virus load; pathogenicity; up-regulation; mitomycin; herpes simplex virus 1; stomach neoplasms; concentration response; stomach tumor; carcinomatosis; antigens, differentiation; differentiation antigen; northern blotting; g 207; herpes virus infection; herpesviridae infections; virulence; viral gene therapy; human herpesvirus 1; humans; human; priority journal; article; ppp1r15a protein, human; ppp1r15a protein, mouse; gadd34 gene
|